Bausch + Lomb Corporation Analysis

Company Overview

Bausch + Lomb Corporation (NYSE: BLCO) is a global entity in eye health, focused on providing solutions related to sight. The company operates in three main divisions: Vision Care, Pharmaceuticals, and Surgery, offering a range of products that include contact lenses, lens care products, and surgical devices.

Corporate Structure

• Employee Count: Approximately 12,900 employees.
• Global Presence: Bausch + Lomb operates in nearly 100 countries.

Recent Developments

On April 30, 2025, Bausch + Lomb reported its first-quarter earnings, indicating a loss and missing revenue estimates. The company announced on June 30, 2023, its plans to acquire Xiidra from Novartis for $1.75 billion, with an additional $750 million contingent on future sales related to Xiidra.

Financial Highlights

• Current Stock Price: $11.1050
• Price Change: -19.06%
• Volume: 153,980 shares traded
• Market Capitalization: Approximately $4.85 billion
• Revenue (TTM): $4.79 billion
• Net Income (TTM): -$317 million
• Earnings Per Share (EPS): -$0.90

Strategic Initiatives

Bausch + Lomb is focusing on:

• Innovation and R&D: Increased investment in research and development to enhance product offerings.
• Market Expansion: Efforts to penetrate emerging markets and strengthen distribution channels.
• Sustainability Practices: Implementation of environmentally friendly initiatives.

Market Position and Industry Context

Bausch + Lomb competes with major players in the eye care market, including Johnson & Johnson, Alcon, and CooperVision. The company holds a substantial market share in contact lenses and lens care products.

Financial Performance Metrics

Metric	Value
Market Cap	$4.85 billion
Revenue (TTM)	$4.79 billion
Net Income (TTM)	-$317 million
EPS	-$0.90
Price/Sales Ratio	1.01
Price/Book Ratio	0.75

TL;DR

Bausch + Lomb Corporation reported a loss in Q1 2025, missing revenue estimates. The stock price is currently at $11.1050, reflecting a 19.06% decrease. The company is acquiring Xiidra from Novartis for $1.75 billion, with additional payments tied to future sales. Bausch + Lomb maintains a focus on innovation, market expansion, and sustainability within the competitive eye care market.